51-Year-Old Man Presents With a Brain Mass

Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.

Data from the phase 2b ReNeu trial may support mirdametinib as a valuable new treatment option for adults and children with NF1-PN.

A PDUFA date has been set for February 28, 2025, for the potential approval of mirdametinib in neurofibromatosis type 1-associated plexiform neurofibromas.

A rare case of spinal atypical teratoid/rhabdoid tumor is presented in an adult man after presenting with neck pain and bilateral upper extremity paralysis.

We spoke with Dr. Priya Kumthekar and Dr. Alexander Stegh about their nucleic acid-based therapeutic development that targets glioblastoma.

Researchers have now mapped genetic changes that help drive glioblastoma and are hoping this will lay the foundation for targeted treatment of the disease.